Drug Profile
Research programme: cancer immunotherapeutics - Shenogen Pharm/Institute of Materia Medica
Latest Information Update: 28 Jan 2022
Price :
$50
*
At a glance
- Originator Institute of Materia Medica; Shenogen Pharma
- Class Antineoplastics; Immunotherapies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer